



Daniel Dietrich

Contact

Daniel Dietrich

Publications (18)

Huober J, Thürlimann B, Dietrich D. Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?–Reply. *JAMA Oncol* 2024

Huober J, Weder P, Ribí K, Thürlimann B, Thery J, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye A, Müller A, Membrez-Antonioli V, Gerard M, Lemonnier J, Hawie H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol* 2023

Stoffel S, Lupatsch J, Schwenkglenks M, Dietrich D, Schär C, Feller A, Anchisi S, von Briel T, Zürrer-Härdi U, Gillissen S, Cathomas R, Thürlimann B, von Moos R, Mark M. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study. *Swiss Med Wkly* 2021; 151:w20464.

Ribi K, von Moos R, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Thürlimann B, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16). *BMC cancer* 2021; 21:182.

Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle D, Rothgiesser K, Pagani O, Thürlimann B. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study – SAKK 22/99. *BMC cancer* 2020; 20:114.

Mark M, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Ribí K, Thürlimann B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). *J Bone Oncol* 2019; 21:100273.

Gargiulo P, Pignata S, Berardi S, Glimelius B, Scheithauer W, Ruhstaller T, Bodoky G, Herrmann R, Dietrich D, Brauchli P. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. *Ther Adv Med Oncol* 2019; 11:1758835918818351.

Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribí K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. *J Geriatr Oncol* 2018; 10:304-310.

Baumann M, Templeton A, Ruhstaller T, Riesen W, Mark M, Klingbiel D, Hochstrasser A, Dietrich D, Dani S, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. *Swiss Med Wkly* 2018; 148:w14576.

Steffen T, Ruhstaller T, Brauchli P, Thierstein S, Schiesser M, Gloor B, Furrer M, Marti W, Huber O, Kettelhack C, Schneider A, Dietrich D, Swiss Group for Clinical Cancer Research (SAKK). Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer. *Ann Surg* 2017; 269:83-87.

Templeton A, Ruhstaller T, Thürlimann B, Zaman K, von Moos R, Rochlitz C, Winterhalder R, von Rohr L, Müller A, Winkler A, Borner M, Dietrich D, Beyeler M, Hsu Schmitz S, Sun H, Surber C, Ribí K, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). *Breast* 2014; 23:244-9.

Templeton A, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. *BMC cancer* 2013; 13:153.

Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). *J Clin Oncol* 2011; 29:626-31.

Strasser F, Müller-Käser I, Dietrich D. Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study. *Journal of pain and symptom management* 2009; 38:505-14.

Koeberle D, Herrmann R, Mora O, Ruhstaller T, Strasser F, Beretta K, Mingrone W, Caspar C, Dietrich D, Gerber D, Borner M, Saletti P, Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3702-8.

Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tamas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3695-701.

Hess V, Scheithauer W, Figer A, Saletti P, Bajetta E, Ruhstaller T, Bodoky G, Dietrich D, Grawe P, Glimelius B, Herrmann R. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. *The lancet oncology* 2008; 9:132-8.

Herrmann R, Stemmer S, Tamas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2007; 25:2212-7.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch